Cargando…
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in clinical practice is still unknown. Data was gathered from 1...
Autores principales: | Fukahori, Masaru, Okabe, Yoshinobu, Shimokawa, Mototsugu, Otsuka, Taiga, Koga, Futa, Ueda, Yujiro, Nakazawa, Junichi, Komori, Azusa, Otsu, Satoshi, Arima, Shiho, Makiyama, Akitaka, Taguchi, Hiroki, Honda, Takuya, Ushijima, Tomoyuki, Miwa, Keisuke, Shibuki, Taro, Nio, Kenta, Ide, Yasushi, Ureshino, Norio, Mizuta, Toshihiko, Mitsugi, Kenji, Shirakawa, Tsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632451/ https://www.ncbi.nlm.nih.gov/pubmed/37938630 http://dx.doi.org/10.1038/s41598-023-46924-0 |
Ejemplares similares
-
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
por: Shibuki, Taro, et al.
Publicado: (2022) -
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Shirakawa, Tsuyoshi, et al.
Publicado: (2023) -
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2021) -
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)